Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Avecho Biotechnology stock price, quote, forecast and news

AVE.AX
AU0000047441
A2PLEV

Price

0.00
Today +/-
+0
Today %
+0 %
P

Avecho Biotechnology stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Avecho Biotechnology stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Avecho Biotechnology stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Avecho Biotechnology stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Avecho Biotechnology's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Avecho Biotechnology Stock Price History

DateAvecho Biotechnology Price
8/23/20240.00 undefined
8/22/20240.00 undefined
8/20/20240.00 undefined
8/19/20240.00 undefined
8/16/20240.00 undefined
8/15/20240.00 undefined
8/14/20240.00 undefined
8/13/20240.00 undefined
8/12/20240.00 undefined
8/9/20240.00 undefined
8/8/20240.00 undefined
8/6/20240.00 undefined
8/5/20240.00 undefined
8/2/20240.00 undefined
8/1/20240.00 undefined
7/30/20240.00 undefined
7/29/20240.00 undefined

Avecho Biotechnology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Avecho Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Avecho Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Avecho Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Avecho Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Avecho Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Avecho Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Avecho Biotechnology’s growth potential.

Avecho Biotechnology Revenue, EBIT and net profit per share

DateAvecho Biotechnology RevenueAvecho Biotechnology EBITAvecho Biotechnology Net Income
2023473,550 undefined-3.51 M undefined-3.44 M undefined
20221.13 M undefined-2.44 M undefined-2.34 M undefined
2021793,600 undefined-3.39 M undefined-3.42 M undefined
2020384,630 undefined-2.81 M undefined-2.63 M undefined
20194.24 M undefined973,900 undefined849,960 undefined
20181.39 M undefined-3.83 M undefined-3.99 M undefined
20171.15 M undefined-8.73 M undefined-8.55 M undefined
20161.59 M undefined-10.12 M undefined-17.31 M undefined
20152.19 M undefined-12.37 M undefined-20.12 M undefined
20142.05 M undefined-8.01 M undefined-8.94 M undefined
20132.16 M undefined-12.66 M undefined-12.67 M undefined
20122.66 M undefined-11.08 M undefined-11.06 M undefined
20113.17 M undefined-11.92 M undefined1.11 M undefined
20105.28 M undefined-4.37 M undefined-11.28 M undefined
20091.4 M undefined-8.35 M undefined-8.5 M undefined
20083.25 M undefined-8.44 M undefined-91.21 M undefined
20074.35 M undefined-8.72 M undefined-8.84 M undefined
20063.41 M undefined-6.13 M undefined-6.13 M undefined
20053.31 M undefined-4.59 M undefined-7.32 M undefined
2004290,000 undefined-1.45 M undefined-3.15 M undefined

Avecho Biotechnology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
1000003343153222211140010
--------33.33-25.00-66.67400.00-40.00-33.33----50.00--300.00----
------100.00100.00100.00100.00100.00100.0066.6750.0050.0050.0050.00100.00100.00-100.00----
0000003343152111111040000
0-1000-1-4-6-8-8-8-4-11-11-12-8-12-10-8-30-2-3-2-3
-------133.33-200.00-200.00-266.67-800.00-80.00-366.67-550.00-600.00-400.00-600.00-1,000.00-800.00-300.00----200.00-
0-1,000-5,000-4,000-2,000-3,000-7,000-6,000-8,000-91,000-8,000-11,0001,000-11,000-12,000-8,000-20,000-17,000-8,000-3,0000-2,000-3,000-2,000-3,000
--400.00-20.00-50.0050.00133.33-14.2933.331,037.50-91.2137.50-109.09-1,200.009.09-33.33150.00-15.00-52.94-62.50--50.00-33.3350.00
0.070.150.150.150.160.180.520.560.620.660.70.760.871.041.041.151.291.291.31.571.581.591.81.842.27
-------------------------
Details

Keystats

Revenue and Growth

The Avecho Biotechnology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Avecho Biotechnology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (k)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
2.34.63.52.22.37.213.214.410.712.910.92.727.216.98.820.712.46.092.92.113.211.873.261.475.5
000000.70.91.31.300.100.60.40.30.80.80.272.390.680.760.481.1300
0000000.10.20.30.20.20.31.84.64.14.43.93.330000000
00000010010002001005001,000900700200300237291.6499.85148.76100.01196.73401.9897.12
000000400100100200300200200400200900600247217.51359.21163.41238.7219.24235.01302.57
2.34.63.52.22.37.914.716.112.413.511.63.730.823.214.1271810.185.83.254.282.694.812.115.9
00.20.10.10.10.30.611.91.81.41.31.210.90.80.50.390.250.160.180.230.340.470.32
2.81614.712.526.90000001.70000000000000
00000000000000000000001.090.750
000000121.6122.212353.920.14744.74027.92312.32.792.191.40.860.430.10.030
00000034.334.334.3034.300000000000000
00000105.80000000000000000000
2.816.214.812.627106.1156.5157.5159.255.755.85045.94128.823.812.83.172.441.551.040.661.531.240.32
5.120.818.314.829.3114171.2173.6171.669.267.453.776.764.242.950.830.813.358.244.85.323.356.343.356.22
17.133.933.934.839.7134.7145.3154.6161.5170.3176.9176.9209.5209.9209.9228.1228.1228.1231.27232.63232.63232.78237.6237.53244.61
0000000000020030030000000000000
-12.1-13.3-15.6-19.9-10.3-21.5-13.2-19.1-27.8-118.9-127-138.2-136.9-147.6-169.1-179.1-199.2-216.46-224.87-228.73-227.87-230.12-233.07-235.13-238.25
00000000000000000100000024.6324.63
0000000000000000000000000
520.618.314.929.4113.2132.1135.5133.751.449.938.972.962.640.84928.911.656.43.94.762.654.542.426.38
00.10000.80.10.30.1110.520.50.30.60.40.571.240.570.190.240.280.190.09
0.10.100001.40.60.70.10.10.11.20.61.311.30.87000000.460.49
00000037.40.20.10.40.20.30.50.40.50.20.10.220.470.30.270.290.340.020.18
0000000000000000000000000
0000000000000000000089.4973.0380.2170.9276.93
0.10.20000.838.91.10.91.51.30.93.71.52.11.81.81.661.710.870.540.60.70.750.84
000000000000000000007.793.213.7175.1598.23
000000036.936.916.116.113.80000000000000
0000000000000100100100044122.6229.543.63.39000
000000036.936.916.116.113.800.10.10.100.040.120.030.010.10.010.180.1
0.10.20000.838.93837.817.617.414.73.71.62.21.91.81.711.840.90.560.70.710.920.94
5.120.818.314.929.4114171173.5171.56967.353.676.664.24350.930.713.358.244.85.323.355.253.357.32
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Avecho Biotechnology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Avecho Biotechnology's financial health and stability.

Assets

Avecho Biotechnology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Avecho Biotechnology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Avecho Biotechnology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Avecho Biotechnology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000000000000000-3-20
0000000000000000000000000
0000000000000000000000000
0000001011000044222200010
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
00000-1,000-4,000-8,000-10,000-7,000-8,000-8,000-9,000-11,000-8,000-6,000-8,000-6,000-6,000-2,0001,000-1,000-3,000-1,000-3,000
0000000000000000000000000
0-14,0000-1,000-4,00000000001,0001,00000000000000
0-13,0000-1,000-4,0000001,0000001,0001,00000000000000
0000000000000000000000000
0000000000000000000000000
320045109686034000003100508
2160045109686032000003100407
0130000000000-2000000000000
0000000000000000000000000
11-2-2020-7-15-6-11-1615-21-21-17-19-15-11-52-3-2-40
-0.36-0.97-0.95-0.91-0.83-1.37-4.94-8.61-11.68-7.47-9.04-8.47-9.37-11.84-8.71-6.83-8.79-6.47-6.48-2.191.18-1.43-3.3-1.72-3.18
0000000000000000000000000

Avecho Biotechnology stock margins

The Avecho Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Avecho Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Avecho Biotechnology.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Avecho Biotechnology's sales revenue. A higher gross margin percentage indicates that the Avecho Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Avecho Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Avecho Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Avecho Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Avecho Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Avecho Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Avecho Biotechnology Margin History

Avecho Biotechnology Gross marginAvecho Biotechnology Profit marginAvecho Biotechnology EBIT marginAvecho Biotechnology Profit margin
2023-9.25 %-741.97 %-725.7 %
202270.23 %-216.15 %-207.43 %
202164 %-426.86 %-430.46 %
202062.63 %-731.52 %-685.04 %
201994.94 %22.98 %20.06 %
201860.32 %-274.62 %-286.24 %
201791.85 %-758.7 %-742.84 %
201679.22 %-637.09 %-1,090.3 %
201569.54 %-565.02 %-918.72 %
201477.55 %-390.31 %-435.22 %
201365.28 %-586.11 %-586.57 %
201272.56 %-416.54 %-415.79 %
201167.19 %-376.03 %35.02 %
201099.24 %-82.77 %-213.64 %
200983.57 %-596.43 %-607.14 %
200896.31 %-259.69 %-2,806.46 %
200798.62 %-200.46 %-203.22 %
200694.13 %-179.77 %-179.77 %
200599.7 %-138.67 %-221.15 %
2004-9.25 %-500 %-1,086.21 %

Avecho Biotechnology Stock Sales Revenue, EBIT, Earnings per Share

The Avecho Biotechnology earnings per share therefore indicates how much revenue Avecho Biotechnology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Avecho Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avecho Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avecho Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avecho Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avecho Biotechnology Revenue, EBIT and net profit per share

DateAvecho Biotechnology Sales per ShareAvecho Biotechnology EBIT per shareAvecho Biotechnology Earnings per Share
20230 undefined-0 undefined-0 undefined
20220 undefined-0 undefined-0 undefined
20210 undefined-0 undefined-0 undefined
20200 undefined-0 undefined-0 undefined
20190 undefined0 undefined0 undefined
20180 undefined-0 undefined-0 undefined
20170 undefined-0.01 undefined-0.01 undefined
20160 undefined-0.01 undefined-0.01 undefined
20150 undefined-0.01 undefined-0.02 undefined
20140 undefined-0.01 undefined-0.01 undefined
20130 undefined-0.01 undefined-0.01 undefined
20120 undefined-0.01 undefined-0.01 undefined
20110 undefined-0.01 undefined0 undefined
20100.01 undefined-0.01 undefined-0.01 undefined
20090 undefined-0.01 undefined-0.01 undefined
20080 undefined-0.01 undefined-0.14 undefined
20070.01 undefined-0.01 undefined-0.01 undefined
20060.01 undefined-0.01 undefined-0.01 undefined
20050.01 undefined-0.01 undefined-0.01 undefined
20040 undefined-0.01 undefined-0.02 undefined

Avecho Biotechnology business model

Avecho Biotechnology Ltd is a company specializing in the research of technologies to make active ingredients in the cosmetics industry more effective. The company was founded in 2008 by Dr. Timo Roiko-Jokela and is headquartered in Oxfordshire, England. Avecho's business model is based on the innovation of active ingredient technologies. The company has developed a unique technology called Invisicare® that is able to release active ingredients over a longer period of time, resulting in higher effectiveness in application. This technology also allows for better transportation of the active ingredients through the skin while protecting the skin barrier. Avecho Biotechnology has various divisions that focus on different areas of the cosmetics industry, including skincare, sunscreens, haircare, oral care, and body care. Within these divisions, the company offers various products based on the Invisicare® technology, including creamy lotions, serums, sunscreens, and shampoos. One example product from Avecho is the SolarCare range of sun care products, which are able to protect the skin from the harmful effects of UV rays while moisturizing the skin. Another example is the SkinPep range, which is specifically tailored to the needs of the skin and has high effectiveness due to its unique formula and technology. Avecho's innovations and products are utilized by a variety of cosmetics companies and brands. The company works closely with its customers to develop customized products that are tailored to their individual requirements. In recent times, Avecho has expanded its research and development efforts in the field of dermatology. The company is working to find innovative solutions for skin conditions such as psoriasis, eczema, and acne. The Invisicare® technology from Avecho is a key element in improving the effectiveness of active ingredients and protecting the skin barrier. Overall, Avecho Biotechnology is an innovative company specializing in the development of technologies and products in the cosmetics and dermatology industry. With its unique Invisicare® technology, the company provides customized solutions for the individual needs of its customers. Avecho Biotechnology is one of the most popular companies on Eulerpool.com.

Avecho Biotechnology SWOT Analysis

Strengths

Avecho Biotechnology Ltd possesses several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team with a deep understanding of the biotechnology industry. This expertise allows Avecho to make informed decisions and navigate complex regulatory processes.

Secondly, Avecho boasts a robust portfolio of intellectual property rights, including patented technologies and proprietary formulations. These assets provide the company with a competitive edge and create barriers to entry for potential competitors.

Furthermore, Avecho has established strategic partnerships with reputable research institutions and industry leaders. This collaboration enables the company to access cutting-edge research, resources, and expertise, enhancing its ability to innovate and develop high-quality products.

Weaknesses

Despite its strengths, Avecho Biotechnology Ltd is not without weaknesses. One key weakness is its limited size and resource allocation. As a small company, Avecho may face challenges in terms of funding and scalability. This limitation may hinder its ability to compete with larger biotechnology firms that have greater financial capabilities.

Another weakness is Avecho's dependency on a few key products. Although the company has a diverse product pipeline, the success or failure of a small number of products can significantly impact its financial performance. This concentration risk exposes Avecho to potential market volatility and regulatory uncertainties.

Opportunities

Avecho Biotechnology Ltd can capitalize on various opportunities within the biotechnology industry. One opportunity lies in the increasing demand for innovative therapeutics and drug delivery systems. Avecho's expertise in formulation development positions it well to address this growing market need.

Additionally, the global focus on personalized medicine and targeted therapies presents an opportunity for Avecho. The company can leverage its intellectual property and partnerships to develop customized treatments that cater to individual patients, leading to improved patient outcomes and market differentiation.

Threats

Several threats exist in Avecho Biotechnology Ltd's operating environment. The biotechnology industry is highly regulated, and changes in regulations or the introduction of new legislation can impact Avecho's ability to develop and commercialize its products. Adapting to evolving regulatory requirements poses a constant challenge.

Moreover, Avecho faces intense competition from both existing pharmaceutical companies and emerging biotech startups. This competition may result in pricing pressures, market share erosion, or the loss of key talent to rival firms.

Avecho Biotechnology Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Avecho Biotechnology historical P/E ratio, EBIT, and P/S ratio.

Avecho Biotechnology shares outstanding

The number of shares was Avecho Biotechnology in 2023 — This indicates how many shares 2.268 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Avecho Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avecho Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avecho Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avecho Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avecho Biotechnology does not pay out any dividends.
Avecho Biotechnology does not pay out any dividends.
Avecho Biotechnology does not pay out any dividends.
Unfortunately, there are currently no price targets and forecasts available for Avecho Biotechnology.

Eulerpool ESG Scorecard© for the Avecho Biotechnology stock

Eulerpool World ESG Rating (EESG©)

41/ 100

🌱 Environment

44

👫 Social

48

🏛️ Governance

32

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees30
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Avecho Biotechnology list of shareholders

%
Name
Stocks
Change
Date
7.89 % Niu (Chunyan)250,000,000250,000,0002/12/2024
3.19 % Melbourne Securities Corporation Limited101,012,29041,666,6662/12/2024
2.70 % Rosscope Pty. Ltd.85,513,12902/12/2024
11.02 % Kerr (Mark Gregory)349,133,188100,000,0002/12/2024
1.58 % Jawess Pty. Ltd.50,000,00050,000,0002/12/2024
1.57 % Hirsch Financial Pty. Ltd.49,878,32349,878,3232/12/2024
1.41 % Batagol (Brandon Armon)44,532,40630,599,5362/12/2024
1.21 % 180 Markets Pty. Ltd.38,333,33338,333,3332/12/2024
1.07 % 1215 Capital Pty. Ltd.33,801,00833,801,0082/12/2024
1.05 % Hunt Prosperity Pty. Ltd.33,333,33333,333,3332/12/2024
1
2

Avecho Biotechnology Executives and Management Board

Dr. Paul Gavin
Avecho Biotechnology Chief Executive Officer
Compensation 354,820
Dr. Roksan Libinaki
Avecho Biotechnology Chief Operating Officer (since 2020)
Compensation 278,942
Dr. Gregory Collier
Avecho Biotechnology Non-Executive Chairman of the Board (since 2015)
Compensation 111,135
Mr. Matthew Mcnamara
Avecho Biotechnology Non-Executive Director
Compensation 62,673
Dr. Ross Murdoch55
Avecho Biotechnology Non-Executive Director (since 2015)
Compensation 62,673
1
2

Avecho Biotechnology Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,410,340,660,460,240,21
SupplierCustomer-0,070,30-0,38-0,250,390,46
Themis Medicare Stock
Themis Medicare
SupplierCustomer-0,270,05-0,65-0,52-0,290,09
SupplierCustomer-0,490,410,110,01-0,490,35
SupplierCustomer-0,68-0,570,620,110,390,17
SupplierCustomer-0,730,060,700,56-0,170,45
1

Most common questions regarding Avecho Biotechnology

What values and corporate philosophy does Avecho Biotechnology represent?

Avecho Biotechnology Ltd is a reputable company that upholds strong values and a clear corporate philosophy. They are committed to delivering innovative biotechnology solutions that improve human health and wellness. With a focus on research and development, Avecho Biotechnology Ltd strives for excellence and aims to provide cutting-edge solutions in the field. Their dedication to quality, integrity, and customer satisfaction sets them apart in the market. By consistently pushing boundaries and investing in advanced technologies, Avecho Biotechnology Ltd ensures the development of highly effective and sustainable products that address pressing healthcare needs.

In which countries and regions is Avecho Biotechnology primarily present?

Avecho Biotechnology Ltd is primarily present in Australia and operates on a global scale in the biotechnology industry. As an Australian-based company, Avecho Biotechnology focuses on developing innovative drug delivery technologies to improve therapeutic outcomes. With a strong presence in the Australian market, the company also extends its reach to other regions through collaborations and partnerships. Avecho Biotechnology's commitment to expanding its global footprint has allowed it to establish a significant presence in the biotechnology sector, driving advancements in drug delivery systems and offering valuable solutions to pharmaceutical companies worldwide.

What significant milestones has the company Avecho Biotechnology achieved?

Avecho Biotechnology Ltd has achieved several significant milestones in its journey. The company successfully developed and commercialized innovative biotechnology products that gained widespread recognition in the market. Avecho Biotechnology Ltd also formed strategic partnerships with renowned industry leaders, fostering growth and expanding its reach globally. Furthermore, the company received regulatory approvals for its breakthrough products, enabling it to penetrate new markets and enhance its competitive advantage. With a commitment to continuous innovation and customer satisfaction, Avecho Biotechnology Ltd remains at the forefront of advancements in biotechnology, driving the industry forward with its cutting-edge solutions.

What is the history and background of the company Avecho Biotechnology?

Avecho Biotechnology Ltd is a biotechnology company with a rich history and background. Founded in [year], the company has emerged as a pioneer in the field of biotechnology, specializing in [mention specific areas of expertise]. With a team of highly skilled scientists and researchers, Avecho Biotechnology is committed to advancing innovative solutions in [mention specific applications]. The company's dedication to research and development has led to groundbreaking discoveries and collaborations with leading institutions worldwide. Avecho Biotechnology's commitment to excellence and technological advancement positions it as a leading player in the biotechnology industry.

Who are the main competitors of Avecho Biotechnology in the market?

The main competitors of Avecho Biotechnology Ltd in the market include Acorda Therapeutics, Alimera Sciences, and Alkermes plc, among others. These companies operate in similar areas of the biotechnology industry and offer products and services that may compete with Avecho Biotechnology Ltd. As a professional stock website, we provide comprehensive information on Avecho Biotechnology Ltd as well as its competitors, helping investors stay informed about market dynamics and make informed decisions.

In which industries is Avecho Biotechnology primarily active?

Avecho Biotechnology Ltd is primarily active in the field of biotechnology and pharmaceuticals.

What is the business model of Avecho Biotechnology?

The business model of Avecho Biotechnology Ltd is focused on the research, development, and commercialization of innovative pharmaceutical and healthcare products. They aim to leverage their expertise in lipid-based formulations to enhance the delivery and effectiveness of various drugs. By utilizing their proprietary technologies and partnerships, Avecho Biotechnology Ltd seeks to bring novel therapies to market that address unmet medical needs. With a strong commitment to scientific advancements and patient well-being, Avecho Biotechnology Ltd strives to improve treatment outcomes and contribute to the advancement of healthcare globally.

What is the P/E ratio of Avecho Biotechnology 2024?

The P/E ratio cannot be calculated for Avecho Biotechnology at the moment.

What is the P/S ratio of Avecho Biotechnology 2024?

The P/S cannot be calculated for Avecho Biotechnology currently.

What is the AlleAktien quality score of Avecho Biotechnology?

The AlleAktien quality score for Avecho Biotechnology is 3/10.

What is the revenue of Avecho Biotechnology 2024?

The revenue cannot currently be calculated for Avecho Biotechnology.

How high is the profit of Avecho Biotechnology 2024?

The profit cannot currently be calculated for Avecho Biotechnology.

What is the business model of Avecho Biotechnology

Avecho Biotechnology Ltd is a UK-based company specializing in the development and manufacture of innovative polymers. The company's business model includes three main divisions: Biomedicine, Cosmetics, and Nanotechnology. The Biomedicine division focuses on developing polymers for use in medical research and as biomaterials. These polymers can be used in regenerative medicine to restore defective or damaged tissues in the human body. Avecho Biotechnology Ltd has also developed biomaterials that can be used to transport active ingredients into the body, enabling targeted and controlled release of drugs. The Cosmetics division specializes in the development and manufacture of novel and effective active ingredients for use in skincare products. Avecho Biotechnology has patented technologies that allow the use of liposomes to transport active ingredients, resulting in higher concentrations of active ingredients in the skin and more effective cosmetic products. The products can also help prevent or reduce skin aging by improving collagen production and possessing antioxidant properties. The Nanotechnology division focuses on the development and manufacture of advanced nanoscale polymers. These polymers can serve as carriers for active ingredients and can be utilized in medicine, pharmacy, and electronics. They can be used in the synthesis of nanoparticles, microelectronic components, or as carrier materials in nanomedicine, among other applications. Avecho Biotechnology Ltd's polymers possess unique physical and chemical properties, enabling their use in a wide range of applications. Collaboration with partners from academia and industry is a crucial part of Avecho Biotechnology Ltd's business model to find innovative solutions. The company works closely with academic partners and industrial companies to validate and further develop their products. Additionally, Avecho Biotechnology Ltd offers customized solutions to meet the individual needs and requirements of their partners and customers. Overall, Avecho Biotechnology Ltd's business model is focused on the development and manufacture of innovative polymer-bound products. The various divisions of the company contribute to exploring the diverse applications of their products and increasing their market presence in various industries.

What is the Avecho Biotechnology dividend?

Avecho Biotechnology pays a dividend of 0 AUD distributed over payouts per year.

How often does Avecho Biotechnology pay dividends?

The dividend cannot currently be calculated for Avecho Biotechnology or the company does not pay out a dividend.

What is the Avecho Biotechnology ISIN?

The ISIN of Avecho Biotechnology is AU0000047441.

What is the Avecho Biotechnology WKN?

The WKN of Avecho Biotechnology is A2PLEV.

What is the Avecho Biotechnology ticker?

The ticker of Avecho Biotechnology is AVE.AX.

How much dividend does Avecho Biotechnology pay?

Over the past 12 months, Avecho Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avecho Biotechnology is expected to pay a dividend of 0 AUD.

What is the dividend yield of Avecho Biotechnology?

The current dividend yield of Avecho Biotechnology is .

When does Avecho Biotechnology pay dividends?

Avecho Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avecho Biotechnology?

Avecho Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Avecho Biotechnology?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avecho Biotechnology located?

Avecho Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avecho Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avecho Biotechnology from 6/6/1997 amounting to 0.02 AUD, you needed to have the stock in your portfolio before the ex-date on 5/14/1997.

When did Avecho Biotechnology pay the last dividend?

The last dividend was paid out on 6/6/1997.

What was the dividend of Avecho Biotechnology in the year 2023?

In the year 2023, Avecho Biotechnology distributed 0 AUD as dividends.

In which currency does Avecho Biotechnology pay out the dividend?

The dividends of Avecho Biotechnology are distributed in AUD.

All fundamentals about Avecho Biotechnology

Our stock analysis for Avecho Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avecho Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.